Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 129, Issue 3-5, 2012, Pages 179-190

  Nishiyama, Tsutomu ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Androgen deprivation therapy; Intra prostatic androgen metabolism; Prostate cancer; Radiotherapy; Toxicity

Indexed keywords

ANDROSTANOLONE; CORTICOTROPIN;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; PROSTATE CANCER; REVIEW; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 84858292115     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2011.12.019     Document Type: Review

References (123)

1. G.P. Haas, N. Delongchamps, O.W. Brawley, C.Y. Wang, and G. de la Roza The worldwide epidemiology of prostate cancer: perspectives from autopsy studies Can. J. Urol. 15 2008 3866 3871
2. K.L. Greene, J.E. Cowan, M.R. Cooperberg, M.V. Meng, J. DuChane, l.P.R. Carrol Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators Who is the average patient presenting with prostate cancer? Urology 66 5 Suppl. 2005 76 82 (Pubitemid 41356563)
3. A.V. D'Amico, J. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era J. Clin. Oncol. 21 2003 2163 2172 (Pubitemid 46606365)
4. M.R. Cooperberg, D.J. Pasta, E.P. Elkin, M.S. Litwin, D.M. Latini, J. Du Chane, and P.R. Carroll The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J. Urol. 173 2005 1938 1942 (Pubitemid 40675216)
5. C. Huggins, and C.V. Hodges Studies on prostate cancer. Effect of castration. estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293 297
6. D.G. McLeod, E.D. Crawford, and E.P. DeAntoni Combined androgen blockade: the gold standard for metastatic prostate cancer Eur. Urol. 32 1997 70 77 (Pubitemid 27355067)
7. K.J. Pienta, and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer Clin. Cancer Res. 12 2006 1665 1671
8. G. Di Lorenzo, C. Buonerba, R. Autorino, S. De Placido, and C.N. Sternberg Castration-resistant prostate cancer: current and emerging treatment strategies Drugs 70 2010 983 1000
9. D.A. Kuban, H.D. Thames, L.B. Levy, E.M. Horwitz, P.A. Kupelian, A.A. Martinez, J.M. Michalski, T.M. Pisansky, H.M. Sandler, W.U. Shipley, M.J. Zelefsky, and A.L. Zietman Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era Int. J. Radiat. Oncol. Biol. Phys. 57 2003 915 928 (Pubitemid 37324109)
10. Endogenous Hormones and Prostate Cancer Collaborative Group, A.W., Roddam, N.E., Allen, P. Appleby, T.J. Key, Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies, J. Natl. Cancer Inst. 100 (2008) 170-183. (Pubitemid 351480553)
11. J.M. Weiss, W.Y. Huang, S. Rinaldi, T.R. Fears, N. Chatterjee, A.W. Hsing, E.D. Crawford, G.L. Andriole, R. Kaaks, and R.B. Hayes Endogenous sex hormones and the risk of prostate cancer: a prospective study Int. J. Cancer 122 2008 2345 2350 (Pubitemid 351542341)
12. W. Bartsch, H. Klein, U. Schiemann, H.W. Bauer, and K.D. Voigt Enzymes of androgen formation and degradation in the human prostate Ann. N. Y. Acad. Sci. 595 1990 53 66 (Pubitemid 20282939)
13. T. Nishiyama, Y. Hashimoto, and K. Takahashi The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer Clin. Cancer Res. 10 2004 7121 7126 (Pubitemid 39487695)
14. T. Nishiyama, T. Ikarashi, Y. Hashimoto, K. Suzuki, and K. Takahashi Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score J. Urol. 176 2006 1387 1391 (Pubitemid 44307234)
15. R.T. Prehn On the prevention and therapy of prostate cancer by androgen administration Cancer Res. 59 1999 4161 4164 (Pubitemid 29418717)
16. S.J. Freedland, W.B. Isaacs, E.A. Platz, M.K. Terris, W.J. Aronson, C.L. Amling, J.C. Presti Jr., and C.J. Kane Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study J. Clin. Oncol. 23 2005 7546 7554 (Pubitemid 46291818)
17. T. Kwon, I.G. Jeong, D. You, M.C. Park, J.H. Hong, H. Ahn, and C.S. Kim Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level BJU Int. 106 2010 633 638
18. M.R. Newton, S. Phillips, S.S. Chang, P.E. Clark, M.S. Cookson, R. Davis, J.H. Fowke, S.D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J.D. Blume, J.A. Smith Jr., and D.A. Barocas Smaller prostate size predicts high grade prostate cancer at final pathology J. Urol. 184 2010 930 937
19. I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, L.G. Ford, M.M. Lieber, R.D. Cespedes, J.N. Atkins, S.M. Lippman, S.M. Carlin, A. Ryan, C.M. Szczepanek, J.J. Crowley, and C.A. Coltman Jr. The influence of finasteride on the development of prostate cancer N. Engl. J. Med. 349 2003 215 224 (Pubitemid 36859473)
20. M.A. Rubin, Y. Allory, V. Molinie, X. Leroy, H. Faucon, F. Vacherot, W. Huang, A. Kuten, L. Salomon, X. Rebillard, O. Cussenot, C. Abbou, and A. de la Taille Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome Urology 66 2005 930 934 (Pubitemid 41587134)
21. M.S. Lucia, J.I. Epstein, P.J. Goodman, A.K. Darke, V.E. Reuter, F. Civantos, C.M. Tangen, H.L. Parnes, S.M. Lippman, F.G. La Rosa, M.W. Kattan, E.D. Crawford, L.G. Ford, C.A. Coltman Jr., and I.M. Thompson Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial J. Natl. Cancer Inst. 99 2007 1375 1383 (Pubitemid 351767184)
22. G.L. Andriole, D.G. Bostwick, O.W. Brawley, L.G. Gomella, M. Marberger, F. Montorsi, C.A. Pettaway, T.L. Tammela, C. Teloken, D.J. Tindall, M.C. Somerville, T.H. Wilson, I.L. Fowler, R.S. Rittmaster REDUCE Study Group Effect of dutasteride on the risk of prostate cancer N. Engl. J. Med. 362 2010 1192 1202
23. R. Li, T. Wheeler, H. Dai, A. Frolov, T. Thompson, and G. Ayala High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy Am. J. Surg. Pathol. 28 2004 928 934 (Pubitemid 38856850)
24. K.M. Fung, E.N. Samara, C. Wong, A. Metwalli, R. Krlin, B. Bane, C.Z. Liu, J.T. Yang, J.V. Pitha, D.J. Culkin, B.P. Kropp, T.M. Penning, and H.K. Lin Increased expression of type 2 3 -hydroxysteroid dehydrogenase/type 5 17 -hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma Endocr. Relat. Cancer 13 2006 169 180
25. K. Wako, T. Kawasaki, K. Yamana, K. Suzuki, S. Jiang, H. Umezu, T. Nishiyama, K. Takahashi, T. Hamakubo, T. Kodama, and M. Naito Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer J. Clin. Pathol. 61 2008 448 454 (Pubitemid 351518226)
26. T.J. Maatman, M.K. Gupta, and J.E. Montie Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate J. Urol. 133 1985 620 621 (Pubitemid 15100756)
27. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
28. T. Tammela Endocrine treatment of prostate cancer J. Steroid Biochem. Mol. Biol. 92 2004 287 295 (Pubitemid 40128250)
29. B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone Eur. Urol. Suppl. 4 2005 14 19 (Pubitemid 40780974)
30. E.D. Crawford, and K.O. Rove Incomplete testosterone suppression in prostate cancer N. Engl. J. Med. 363 2010 1976
31. J. Morote, A. Orsola, J. Planas, E. Trilla, C.X. Raventos, L. Cecchini, and R. Catalan Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J. Urol. 178 2007 1290 1295 (Pubitemid 47368393)
32. M. Perachino, V. Cavalli, and F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance BJU Int. 105 2010 648 651
33. F. Labrie, A. Belanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J. Gomez, and B. Candas Gonadotropin-releasing hormone agonists in the treatment of prostate cancer Endocr. Rev. 26 2005 361 379 (Pubitemid 40686649)
34. F. Labrie, A. Belanger, A. Dupont, V. Luu-The, J. Simard, and C. Labrie Science behind total androgen blockade: from gene to combination therapy Clin. Invest. Med. 16 1993 475 492 (Pubitemid 24111962)
35. G.L. Hammond Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues J. Endocrinol. 78 1978 7 19 (Pubitemid 8387819)
36. B. Belanger, A. Belanger, F. Labrie, A. Dupont, L. Cusan, and G. Monfette Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men J. Steroid Biochem. 32 1989 695 698 (Pubitemid 19176012)
37. J. Geller, and J.D. Albert Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH) Urol. Res. 15 1987 151 153 (Pubitemid 17116900)
38. T. Nishiyama, T. Ikarashi, Y. Hashimoto, K. Wako, and K. Takahashi The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score J. Urol. 178 2007 1282 1288
39. S. Arai, Y. Miyashiro, Y. Shibata, Y. Tomaru, M. Kobayashi, S. Honma, and K. Suzuki Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues Steroids 76 2011 301 308
40. M.E. Grossmann, H. Huang, and D.J. Tindall Androgen receptor signaling in androgen-refractory prostate cancer J. Natl. Cancer Inst. 93 2001 1687 1697 (Pubitemid 33130257)
41. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, and S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 66 2006 2815 2825
42. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, and P.S. Nelson Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res. 67 2007 5033 5041 (Pubitemid 46910214)
43. I. Takizawa, T. Nishiyama, N. Hara, E. Isahaya, T. Hoshii, and K. Takahashi Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: tumor malignant potential and androgen milieu Prostate 70 2010 1395 1401
44. I. Takizawa, N. Hara, T. Nishiyama, E. Isahaya, T. Hoshii, and K. Takahashi Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer J. Urol. 184 2010 1971 1976
45. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
46. P.C. Verhagen, F.H. Schröder, L. Collette, and C.H. Bangma Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review Eur. Urol. 58 2010 261 269
47. E.M. Messing, J. Manola, J. Yao, M. Kiernan, D. Crawford, G. Wilding, P.A. di'SantAgnese, D. Trump Eastern Cooperative Oncology Group study EST 3886 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol. 7 2006 472 479 (Pubitemid 43779173)
48. U.E. Studer, P. Whelan, W. Albrecht, J. Casselman, T. de Reijke, D. Hauri, W. Loidl, S. Isorna, S.K. Sundaram, M. Debois, and L. Collette Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J. Clin. Oncol. 24 2006 1868 1876 (Pubitemid 46638985)
49. W.P. Witjes, C.C. Schulman, and F.M. Debruyne Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma Urology 49 Suppl 1997 65 69 (Pubitemid 27133510)
50. F. Labrie, L. Cusan, J.L. Gomez, P. Diamond, R. Suburu, M. Lemay, B. Tetu, Y. Fradet, A. Bélanger, and B. Candas Neoadjuvant hormonal therapy: The Canadian experience Urology 49 Suppl 1997 56 64 (Pubitemid 27140570)
51. S.L. Goldenberg, L.H. Klotz, J. Srigley, M.A. Jewett, D. Mador, Y. Fradet, J. Barkin, J. Chin, J.M. Paquin, M.J. Bullock, and S. Laplante Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer J. Urol. 156 1996 873 877 (Pubitemid 26269791)
52. M.S. Soloway, R. Sharifi, Z. Wajsman, D. McLeod, D.P. Wood Jr., and A. Puras-Baez Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer J. Urol. 154 1995 424 428
53. B.L. Dalkin, F.R. Ahmann, R. Nagle, and C.S. Johnson Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer J. Urol. 155 1996 1357 1360 (Pubitemid 26081239)
54. S. Demaria, B. Ng, M.L. Devitt, J.S. Babb, N. Kawashima, L. Liebes, and S.C. Formenti Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated Int. J. Radiat. Oncol. Biol. Phys. 58 2004 862 870 (Pubitemid 38221143)
55. N.J. Nesslinger, R.A. Sahota, B. Stone, K. Johnson, N. Chima, C. King, D. Rasmussen, D. Bishop, P.S. Rennie, M. Gleave, P. Blood, H. Pai, C. Ludgate, and B.H. Nelson Standard treatments induce antigen-specific immune responses in prostate cancer Clin. Cancer Res. 13 2007 1493 1502 (Pubitemid 46450440)
56. T. Nishiyama, Y. Tomita, and K. Takahashi Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging Urology 63 2004 917 921 (Pubitemid 38596679)
57. J.F. Langenhuijsen, E.N. van Lin, A.L. Hoffmann, I. Spitters-Post, J. Alfred Witjes, J.H. Kaanders, and P.F. Mulders Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy Urol. Oncol. 29 2011 52 57
58. W.G. Smit, P.A. Helle, W.L. van Putten, A.J. Wijnmaalen, J.J. Seldenrath, and B.H. van der Werf-Messing. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose Int. J. Radiat. Oncol. Biol. Phys. 18 1990 23 29 (Pubitemid 20047386)
59. M.J. Zelefsky, and A. Harrison Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy Urology 49 1997 39 45
60. J.J. Coen, A.L. Zietman, H. Thakral, and W.U. Shipley Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases J. Clin. Oncol. 20 2002 3199 3205 (Pubitemid 34831515)
61. E. Bria, F. Cuppone, D. Giannarelli, M. Milella, E.M. Ruggeri, I. Sperduti, P. Pinnaro, E. Terzoli, F. Cognetti, and P. Carlini Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials Cancer 115 2009 3446 3456
62. S.J. Feigenberg, A.L. Hanlon, E.M. Horwitz, R.G. Uzzo, D. Eisenberg, and A. Pollack Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 62 2005 397 405 (Pubitemid 40704456)
63. A.L. Zietman, E.A. Prince, B.M. Nakfoor, and J.J. Park Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system Int. J. Radiat. Oncol. Biol. Phys. 38 1997 1067 1070 (Pubitemid 27353687)
64. A.L. Zietman, E.A. Prince, B.M. Nakfoor, and W.U. Shipley Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results Urology 49 3A Suppl. 1997 74 83 (Pubitemid 27133512)
65. T. Granfors, J.E. Damber, A. Bergh, M. Landstrom, P.O. Lofroth, and A. Widmark Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma Int. J. Radiat. Oncol. Biol. Phys. 39 1997 1031 1036 (Pubitemid 27506154)
66. J.M. Kaminski, A.L. Hanlon, D.L. Joon, M. Meistrich, P. Hachem, and A. Pollack Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth Int. J. Radiat. Oncol. Biol. Phys. 57 2003 24 28 (Pubitemid 36959735)
67. G.D. Stewart, J.A. Ross, D.B. McLaren, C.C. Parker, F.K. Habib, and A.C. Riddick The relevance of a hypoxic tumour microenvironment in prostate cancer BJU Int. 105 2010 8 13
68. B. Movsas, J.D. Chapman, R.E. Greenberg, A.L. Hanlon, E.M. Horwitz, W.H. Pinover, C. Stobbe, and G.E. Hanks Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study Cancer 89 2000 2018 2024
69. B. Movsas, J.D. Chapman, A.L. Hanlon, E.M. Horwitz, R.E. Greenberg, C. Stobbe, G.E. Hanks, P.A. ollack, A hypoxic ratio of prostate pO2/muscle pO2 predicts for biochemical failure in prostate cancer patients, Urology 60 (2002) 634-639. (Pubitemid 35246449)
70. M. Milosevic, P. Chung, C. Parker, R. Bristow, A. Toi, T. Panzarella, P. Warde, C. Catton, C. Menard, A. Bayley, M. Gospodarowicz, and R. Hill Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response Cancer Res. 67 2007 6022 6025 (Pubitemid 47037480)
71. D. Cvetkovic, B. Movsas, A.P. Dicker, A.L. Hanlon, R.E. Greenberg, J.D. Chapman, G.E. Hanks, and J.V. Tricoli Increasing hypoxia correlates with increased expression of the angiogenesis marker, VEGF, in human prostate carcinoma Urology 57 2001 821 825
72. R.K. Jain, N. Safabakhsh, A. Sckell, Y. Chen, P. Jiang, L. Benjamin, F. Yuan, and E. Keshet Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor Proc. Natl. Acad. Sci. U.S.A. 95 1998 10820 11085
73. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
74. J. Folkman Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N. Engl. J. Med. 333 1995 1757 1763
75. D. Fukumura, and R.K. Jain Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization Microvasc. Res. 74 2007 72 84 (Pubitemid 350051025)
76. I.B. Joseph, J.T. Isaacs, Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers, Cancer Res. 57 (1997) 1054-1057. (Pubitemid 27138600)
77. I.B. Joseph, J.B. Nelson, S.R. Denmeade, and J.T. Isaacs Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue Clin. Cancer Res. 3 1997 2507 2511 (Pubitemid 28133175)
78. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am. J. Pathol. 143 1993 401 409 (Pubitemid 24058195)
79. M. Borre, B.V. Offersen, B. Nerstrom, and J. Overgaard Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting Br. J. Cancer 78 1998 940 944 (Pubitemid 28430025)
80. L.A. Mucci, A. Powolny, E. Giovannucci, Z. Liao, S.A. Kenfield, R. Shen, M.J. Stampfer, and S.K. Clinton Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study J. Clin. Oncol. 27 2009 5627 5633
81. J.T. Isaacs, P.I. Lundmo, R. Berges, P. Martikainen, N. Kyprianou, and H.F. English Androgen regulation of programmed death of normal and malignant prostatic cells J. Androl. 13 1992 457 464
82. M.V. Pilepich, K. Winter, M.J. John, J.B. Mesic, W. Sause, P. Rubin, C. Lawton, M. Machtay, and D. Grignon Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int. J. Radiat. Oncol. Biol. Phys. 50 2001 1243 1252 (Pubitemid 32727802)
83. M. Roach 3rd, K. Bae, J. Speight, H.B. Wolkov, P. Rubin, R.J. Lee, C. Lawton, R. Valicenti, D. Grignon, and M.V. Pilepich Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J. Clin. Oncol. 26 2008 585 591 (Pubitemid 351264352)
84. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
85. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295 (Pubitemid 351159365)
86. J.W. Denham, A. Steigler, D.S. Lamb, D. Joseph, H. Mameghan, S. Turner, J. Matthews, I. Franklin, C. Atkinson, J. North, M. Poulsen, D. Christie, N.A. Spry, K.H. Tai, C. Wynne, G. Duchesne, O. Kovacev, C. D'Este Trans-Tasman Radiation Oncology Group Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol. 6 2005 841 850 (Pubitemid 41614795)
87. J.W. Denham, A. Steigler, D.S. Lamb, D. Joseph, S. Turner, J. Matthews, C. Atkinson, J. North, D. Christie, N.A. Spry, K.H. Tai, C. Wynne, and C. D'Este Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol. 12 2011 451 459
88. C.U. Jones, D. Hunt, D.G. McGowan, M.B. Amin, M.P. Chetner, D.W. Bruner, M.H. Leibenhaut, S.M. Husain, M. Rotman, L. Souhami, H.M. Sandler, and W.U. Shipley Radiotherapy and short-term androgen deprivation for localized prostate cancer N. Engl. J. Med. 365 2011 107 118
89. J. Crook, C. Ludgate, S. Malone, J. Lim, G. Perry, L. Eapen, J. Bowen, S. Robertson, and G. Lockwood Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 60 2004 15 23 (Pubitemid 39165464)
90. J. Crook, C. Ludgate, S. Malone, G. Perry, L. Eapen, J. Bowen, S. Robertson, and G. Lockwood Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 73 2009 327 333
91. M. Bolla, L. Collette, L. Blank, P. Warde, J.B. Dubois, R.O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, J. Mattelaer, J. Lopez Torecilla, J.R. Pfeffer, C. Lino Cutajar, A. Zurlo, and M. Pierart Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
92. M. Bolla, G. Van Tienhoven, P. Warde, J.B. Dubois, R.O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, I. Billiet, J.L. Torecilla, R. Pfeffer, C.L. Cutajar, T. Van der Kwast, and L. Collette External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol. 11 2010 1066 1073
93. G.E. Hanks, T.F. Pajak, A. Porter, D. Grignon, H. Brereton, V. Venkatesan, E.M. Horwitz, C. Lawton, S.A. Rosenthal, H.M. Sandler, W.U. Shipley Radiation Therapy Oncology Group Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J. Clin. Oncol. 21 2003 3972 3978 (Pubitemid 46606211)
94. E.M. Horwitz, K. Bae, G.E. Hanks, A. Porter, D.J. Grignon, H.D. Brereton, V. Venkatesan, C.A. Lawton, S.A. Rosenthal, H.M. Sandler, and W.U. Shipley Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J. Clin. Oncol. 26 2008 2497 2504
95. M.V. Pilepich, R. Caplan, R.W. Byhardt, C.A. Lawton, M.J. Gallagher, J.B. Mesic, G.E. Hanks, C.T. Coughlin, A. Porter, W.U. Shipley, and D. Grignon Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31 J. Clin. Oncol. 15 1997 1013 1021 (Pubitemid 27106285)
96. M.V. Pilepich, K. Winter, C.A. Lawton, R.E. Krisch, H.B. Wolkov, B. Movsas, E.B. Hug, S.O. Asbell, and D. Grignon Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int. J. Radiat. Oncol. Biol. Phys. 61 2005 1285 1290 (Pubitemid 40470408)
97. C.A. Lawton, K. Winter, D. Grignon, and M.V. Pilepich Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31 J. Clin. Oncol. 23 2005 800 807 Erratum in: J Clin Oncol. 23 (2005) 8921 (Pubitemid 46224179)
98. M. Bolla, T.M. de Reijke, G. Van Tienhoven, A.C. Van den Bergh, J. Oddens, P.M. Poortmans, E. Gez, P. Kil, A. Akdas, G. Soete, O. Kariakine, E.M. van der Steen-Banasik, E. Musat, M. Pierart, M.E. Mauer, L. Collette EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group Duration of androgen suppression in the treatment of prostate cancer N. Engl. J. Med. 360 2009 2516 2527
99. A. Widmark, O. Klepp, A. Solberg, J.E. Damber, A. Angelsen, P. Fransson, J.A. Lund, I. Tasdemir, M. Hoyer, F. Wiklund, S.D. Fossa Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308 Erratum in: Lancet. 373 (2009) 1174
100. P. Warde, M. Mason, K. Ding, P. Kirkbride, M. Brundage, R. Cowan, M. Gospodarowicz, K. Sanders, E. Kostashuk, G. Swanson, J. Barber, A. Hiltz, M.K. Parmar, J. Sathya, J. Anderson, C. Hayter, J. Hetherington, M.R. Sydes, W. Parulekar; for the NCIC CTG PR.3/MRC UK PR07 investigators, Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, Lancet (2011) Nov 2 (Epub ahead of print).
101. M. Roach 3rd, M. DeSilvio, C. Lawton, V. Uhl, M. Machtay, M.J. Seider, M. Rotman, C. Jones, S.O. Asbell, R.K. Valicenti, S. Han, C.R. Thomas Jr., W.S. Shipley Radiation Therapy Oncology Group 9413 Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J. Clin. Oncol. 21 2003 1904 1911 (Pubitemid 46606377)
102. C.A. Lawton, M. DeSilvio, M. Roach 3rd, V. Uhl, R. Kirsch, M. Seider, M. Rotman, C. Jones, S. Asbell, R. Valicenti, S. Hahn, and C.R. Thomas Jr. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int. J. Radiat. Oncol. Biol. Phys. 69 2007 646 655 (Pubitemid 47418390)
103. M. Roach 3rd, M. DeSilvio, R. Valicenti, D. Grignon, S.O. Asbell, C. Lawton, C.R. Thomas Jr., and W.U. Shipley Whole-pelvis, mini-pelvis, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int. J. Radiat. Oncol. Biol. Phys. 66 2006 647 653 (Pubitemid 44436716)
104. J. Laverdire, A. Nabid, De L.D. Bedoya, A. Ebacher, A. Fortin, C.S. Wang, and F. Harel The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J. Urol. 171 2004 1137 1140 (Pubitemid 38327543)
105. J.G. Armstrong, C.M. Gillham, M.T. Dunne, D.A. Fitzpatrick, M.A. Finn, M.E. Cannon, J.C. Taylor, C.M. O'Shea, S.J. Buckney, and P.G. Thirion A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 81 2011 35 45
106. L. Souhami, K. Bae, M. Pilepich, and H. Sandler Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31 J. Clin. Oncol. 27 2009 2137 2143
107. A.V. D'Amico, J.W. Denham, M. Bolla, L. Collette, D.S. Lamb, K.H. Tai, A. Steigler, and M.H. Chen Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate Cancer 109 2007 2004 2010 (Pubitemid 46744194)
108. F. Cuppone, E. Bria, D. Giannarelli, V. Vaccaro, M. Milella, C. Nistic, E.M. Ruggeri, I. Sperduti, S. Bracarda, P. Pinnar, G. Lanzetta, P. Muti, F. Cognetti, and P. Carlini Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials BMC Cancer 10 2010 675
109. A. Alexander, J. Crook, S. Jones, S. Malone, J. Bowen, P. Truong, H. Pai, and C. Ludgate Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial Int. J. Radiat. Oncol. Biol. Phys. 76 2010 23 30
110. R. de Crevoisier, K. Slimane, T. Messai, P. Wibault, F. Eschwege, A. Bossi, S. Koscielny, A. Bridier, C. Massard, and K. Fizazi Early PSA decrease is
111. A.V. D'Amico, M.H. Chen, M. de Castro, M. Loffredo, D.S. Lamb, A. Steigler, P.W. Kantoff, J.W. Denham, Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. (2011) Nov 21 (Epub ahead of print).
112. T. Nishiyama, F. Ishizaki, T. Anraku, H. Shimura, and K. Takahashi The influence of androgen deprivation therapy on metabolism in patients with prostate cancer J. Clin. Endocrinol. Metab. 90 2005 657 660 (Pubitemid 40279176)
113. N. Sharifi, J.L. Gulley, and W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2005 238 244 (Pubitemid 41043794)
114. S.M. Alibhai, S. Gogov, and Z. Allibhai Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review Crit. Rev. Oncol. Hematol. 60 2006 201 215 (Pubitemid 44709617)
115. S.L. Greenspan, P. Coates, S.M. Sereika, J.B. Nelson, D.L. Trump, and N.M. Resnick Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer J. Clin. Endocrinol. Metab. 90 2005 6410 6417 (Pubitemid 41759293)
116. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J. Clin. Oncol. 24 2006 4448 4456 (Pubitemid 46630983)
117. C.S. Saigal, J.L. Gore, T.L. Krupski, J. Hanley, M. Schonlau, M.S. Litwin the Urologic Diseases in America Project Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500 (Pubitemid 47463063)
118. H.K. Tsai, A.V. D'Amico, N. Sadetsky, M.H. Chen, and P.R. Carroll Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J. Natl. Cancer Inst. 99 2007 1516 1524 (Pubitemid 351767235)
119. J.A. Efstathiou, K. Bae, W.U. Shipley, G.E. Hanks, M.V. Pilepich, H.M. Sandler, and M.R. Smith Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J. Clin. Oncol. 27 2009 92 99
120. P.L. Nguyen, Y. Je, F.A.B. Schutz, E. Karen, K.E. Hoffman, J.C. Hu, A. Parekh, A. Joshua, J.A. Beckman, K. Toni, and T.K. Choueiri Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366
121. G.N. Levine, A.V. D'Amico, P. Berger, P.E. Clark, R.H. Eckel, N.L. Keating, R.V. Milani, A.I. Sagalowsky, M.R. Smith, N. Zakai American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology CA Cancer J. Clin. 60 2010 194 201
122. S. Punnen, M.R. Cooperberg, N. Sadetsky, and P.R. Carroll Androgen deprivation therapy and cardiovascular risk J. Clin. Oncol. 29 2011 3510 3516
123. L. Bourke, T.J. Chico, P.C. Albertsen, F.C. Hamdy, D.J. Rosario, Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved. Heart (2011) Dec 7 (Epub ahead of print).